The rate of permanent hypothyroidism after a standard 10 mCi radioactive iodine dose is much lower than what other studies report with higher doses, suggesting that this fixed dose may not work well for many patients, especially those with larger thyroids or higher antibody levels.
Claim Context
In patients with Graves' disease treated with radioactive iodine, the rate of permanent hypothyroidism at 6 months after a fixed 10 mCi dose is substantially lower than rates reported in larger studies using higher or calculated doses, suggesting that fixed-dose regimens may be suboptimal in certain patient subgroups.
“The cure rate is lower than the reported by Mohamadien et al, Yang et al, De Jong et al, and Karyampudi et al (79,7%; 76%; 74%; 61,1% respectively). The possible discrepancy causes are small sample size, lower fixed-dose given and delayed second dose administration.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
The comparative effectiveness of fixed 10 mCi versus higher fixed doses (15 mCi) or calculated doses in achieving permanent hypothyroidism at 6 and 12 months in Graves' disease patients.
A systematic review and meta-analysis of all prospective studies comparing fixed 10 mCi, 15 mCi, and calculated RAI doses in Graves' disease, with standardized definitions of permanent hypothyroidism (TSH >10 mIU/L at 12 months), including at least 3000 patients across 40+ studies, stratified by baseline thyroid volume and TRAb.
Whether a fixed 15 mCi RAI dose achieves higher rates of permanent hypothyroidism at 6 months than a fixed 10 mCi dose in Graves' disease patients.
A double-blind RCT of 250 adults with Graves' disease and prior ATD failure, randomized to fixed 10 mCi or 15 mCi RAI, with primary outcome of permanent hypothyroidism (TSH >10 mIU/L on two occasions >3 months apart) at 6 months, controlling for baseline thyroid volume and TRAb.
The association between fixed RAI dose (10 mCi vs. 15 mCi) and rate of permanent hypothyroidism at 6 months in a real-world population of Graves' disease patients.
A prospective cohort study of 400 adults with Graves' disease treated with either fixed 10 mCi or 15 mCi RAI, with serial TSH and FT4 measurements at 3, 6, 12, and 24 months, and baseline collection of thyroid volume, TRAb, smoking status, and goiter size.
The prevalence of permanent hypothyroidism at a single time point (6 months) after fixed-dose RAI in Graves' disease patients.
A cross-sectional survey of 500 adults with Graves' disease who received fixed 10 mCi or 15 mCi RAI at least 6 months prior, measuring current TSH and FT4 levels and collecting retrospective data on baseline characteristics and treatment history.
Anecdotal observations of hypothyroidism development after fixed-dose RAI in individual patients.
A case series of 15–20 patients with Graves' disease treated with fixed 10 mCi or 15 mCi RAI, documenting individual TSH and FT4 trajectories over 12 months, including unusual responses such as delayed hypothyroidism.